||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 523 active entries
710 W. Main St
Durham, NC 27701, USA
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
AlphaVax, Inc., based in Durham, North
Carolina, has been established to commercialize the proprietary AlphaVax vector system, an innovative vaccine delivery technology. The AlphaVax technology constitutes a major advance in vector technology and presents the opportunity to immunize against diseases not currently preventable with vaccines and to substantially improve existing vaccines. Immediate applications of the vectors include preventative and therapeutic human vaccines for infectious diseases and cancer and the production of vaccine intermediates and therapeutic proteins. AlphaVax is focusing on an aggressive development plan for a vaccine to treat human immunodeficiency virus (HIV) due to the critical need for new preventative measures and accelerated development timelines.
The AlphaVax vectors are derived from an avirulent form of Venezuelan equine encephalitis (VEE) virus, and have multiple distinct advantages over other vaccine technologies. These advantages include:
- natural targeting to the antigen-processing cells of the immune system,
- high antigen expression levels,
- induction of broad and robust humoral, cellular, and mucosal immune responses,
- sustained efficacy over multiple simultaneous or sequential inoculations, and
- a high margin of safety.
AlphaVax products will target the human vaccine market, which exceeded $3.5 billion in 1996 and is growing at 15% annually. Expansion of this market should be sustained over the next decade as increasing emphasis is placed on preventative medicines by cost-conscious healthcare providers and as technical advances expand the range of diseases which can be prevented through immunization.
Last update of this entry: before October 1999.